Objectives: A new VITEK w 2 antibiotic susceptibility testing (AST) card, AST N-054, was introduced for aerobic Gram-negative bacilli in 2007 and has been widely adopted for routine use in the UK. We evaluated its performance for detecting extended-spectrum b-lactamase (ESBL) production in Escherichia coli.
Introduction
The Health Protection Agency (HPA) in the UK has published a National Standard Method on the Laboratory detection and reporting of bacteria with extended-spectrum b-lactamase (ESBL) enzymes. 1 A strategy of screening followed by confirmation, typically based on an antibiotic disc method, is recommended. The document states that automated systems, for example, VITEK (bioMérieux S.A., Marcy l'Etoilé, France) and Phoenix (Becton Dickinson Diagnostic Systems, Sparks, MD, USA), which incorporate ESBL detection tests or strategies, are an alternative to the present recommendations. This view was supported by successful detection of 126 (92%) of 137 ESBL producers in a validation trial of the VITEK w 2 Advanced Expert System (AES) with antibiotic susceptibility testing (AST) card, AST N-010. 2 A new AST card, AST N-054, was introduced for testing aerobic Gram-negative bacilli on VITEK w 2 systems in 2007 and has been widely adopted for routine use in the UK. We evaluated its performance for the detection of CTX-M ESBL production in Escherichia coli. 
Methods
One hundred and thirty-seven ESBL-producing E. coli were recovered from faecal samples from nursing home residents during a separate epidemiological study (M. C. O'Leary, P. Donaghy, A. C. Loughrey, P. J. Rooney, J. A. Buchanan, M. M. Merron, B. Smyth, unpublished results). All gave 8-fold synergy between cefotaxime and clavulanate in agar dilution tests by the British Society for Antimicrobial Chemotherapy method, and all were inferred to produce CTX-M-type enzymes based on greater resistance to cefotaxime than to ceftazidime. PCR for a characteristic IS26-bla CTX-M-15 link 3 showed that 73 belonged to strain A, which typically produces a low level of CTX-M-15 enzyme; 4 64 were nonstrain A and their CTX-M enzymes remain to be fully identified. The isolates were stored in pure culture in horse blood at 2808C.
After thawing, isolates were cultured on Columbia blood agar (Oxoid, Basingstoke, UK) at 358C for 18-24 h. These cultures were then used to make suspensions in 0.45% saline, with a turbidity equivalent to a 0. 5 McFarland standard, which were tested (i) using the AST N-054 card on the VITEK w 2 automated system and (ii) with the MASTDISCS w ID ESBL detection disc diffusion test (Mast Diagnostics, Bootle, UK), with the latter performed on MuellerHinton agar (Oxoid) in accordance with the CLSI guidelines. 5 The AST N-054 card tests 20 antimicrobials: ampicillin, amoxicillin/clavulanic acid, piperacillin, piperacillin/tazobactam, cefuroxime, cefalotin, cefotaxime, ceftazidime, cefipime, cefoxitin, ertapenem, meropenem, aztreonam, gentamicin, amikacin, tobramycin, nalidixic acid, ciprofloxacin, trimethoprim and nitrofurantoin, and results were interpreted by the software version WSVT2-R04.03. This system presents both the direct result and that as interpreted by the AES. Testing was repeated if suggested by the AES. For the purposes of comparison with the MASTDISCS w result, all interpretations that included 'ESBL' were categorized as successful. The susceptibility results recommended for cefuroxime, cefotaxime, ceftazidime and aztreonam by the AES were also recorded.
The MASTDISCS w ID ESBL detection test employs discs with cefpodoxime 30 mg, cefotaxime 30 mg, ceftazidime 30 mg and combinations of these agents with clavulanic acid 10 mg. Zone sizes were recorded using the MASTASCAN Elite (Mast Diagnostics) zone reader and software, with a positive ESBL result taken as a cefotaxime zone diameter 27 mm or a ceftazidime zone diameter 22 mm and with the zone of inhibition of one or more cephalosporins increased by 5 mm in the presence of clavulanic acid.
Statistical analysis
The sensitivity of each test method was calculated with 95% confidence intervals placed around the sensitivity estimate. Differences in proportions were evaluated using Fisher's exact test.
Results

VITEK w 2 AST N-054 results
The AST N-054 card detected ESBL production in 93 of the 137 isolates tested [test sensitivity 67.9% (95% CI, 59.7 -75.1)]. Strain A accounted for a significant majority of the 44 ESBL detection failures (Table 1) , with 35/73 strain A isolates incorrectly reported compared with 9/64 non-strain A isolates (P , 0.0001). Of the 44 isolates misreported as negative for ESBL production by the AST N-054 card, the AES reported 29 as susceptible to cefotaxime and all as susceptible to ceftazidime and aztreonam. When the AST N-054 card did detect ESBL production, all susceptible results for cefuroxime, cefotaxime, ceftazidime and aztreonam on reports were changed by the AES to 'intermediate'.
Disc testing results
All the isolates (137/137) gave positive disc diffusion screening results with cefotaxime and ceftazidime, based on cefotaxime zone diameters 27 mm. The median zone diameter for cefotaxime was 18 mm (range 6 -25), whereas that for ceftazidime was 24 mm (range 12 -30). The MASTDISCS w method confirmed ESBL production in 135 of the 137 isolates tested [test sensitivity 98.5% (95% CI, 94.5-99.9)]. The median zone diameter enhancement for cefpodoxime by clavulanic acid was 11 mm (range 0 -20), for cefotaxime 10 mm (range 1 -23) and for ceftazidime 5 mm (range 0 -16). For two isolates, the zone diameter enhancement with clavulanic acid was ,5 mm for all three cephalosporins. One of the two isolates was found to be positive by the AST N-054 card, the other was negative by both methods. Using the MASTDISCS w method alone, both would have been reported as susceptible to ceftazidime, with one being reported as intermediate to cefotaxime and the other resistant.
Discussion
Prompt and accurate detection of ESBL production in Enterobacteriaceae is important, as treatment failure and death have been associated with cephalosporin therapy for infections with ESBL producers that appeared susceptible in vitro. 1, 6 Failure to detect ESBL production in this study led to isolates being reported as susceptible to cefotaxime, ceftazidime and aztreonam, contrary to the current UK national guidance. 1 The ability of the VITEK w 2 AES to detect ESBL production in E. coli with the AST N-054 card (sensitivity 67.9%) was poorer than previously reported by other investigators, 2,7 -9 who mostly used a heterogeneous mix of ESBL producers and other AST cards with different combinations of cephalosporins. 2,7 -9 The VITEK w 2 AST N-010 card, which (unlike the AST N-054 card) includes cefpodoxime, successfully detected ESBL production in 5/5 E. coli strain A, 4/4 non-A E. coli with CTX-M-15 
